Cargando…
Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults
IMPORTANCE: The incidence of infection during SARS-CoV-2 viral waves, the factors associated with infection, and the durability of antibody responses to infection among Canadian adults remain undocumented. OBJECTIVE: To assess the cumulative incidence of SARS-CoV-2 infection during the first 2 viral...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851304/ https://www.ncbi.nlm.nih.gov/pubmed/35171263 http://dx.doi.org/10.1001/jamanetworkopen.2021.46798 |
_version_ | 1784652794356039680 |
---|---|
author | Tang, Xuyang Sharma, Abha Pasic, Maria Brown, Patrick Colwill, Karen Gelband, Hellen Birnboim, H. Chaim Nagelkerke, Nico Bogoch, Isaac I. Bansal, Aiyush Newcombe, Leslie Slater, Justin Rodriguez, Peter S. Huang, Guowen Fu, Sze Hang Meh, Catherine Wu, Daphne C. Kaul, Rupert Langlois, Marc-André Morawski, Ed Hollander, Andy Eliopoulos, Demetre Aloi, Benjamin Lam, Teresa Abe, Kento T. Rathod, Bhavisha Fazel-Zarandi, Mahya Wang, Jenny Iskilova, Mariam Pasculescu, Adrian Caldwell, Lauren Barrios-Rodiles, Miriam Mohammed-Ali, Zahraa Vas, Nandita Santhanam, Divya Raman Cho, Eo Rin Qu, Kathleen Jha, Shreya Jha, Vedika Suraweera, Wilson Malhotra, Varsha Mastali, Kathy Wen, Richard Sinha, Samir Reid, Angus Gingras, Anne-Claude Chakraborty, Pranesh Slutsky, Arthur S. Jha, Prabhat |
author_facet | Tang, Xuyang Sharma, Abha Pasic, Maria Brown, Patrick Colwill, Karen Gelband, Hellen Birnboim, H. Chaim Nagelkerke, Nico Bogoch, Isaac I. Bansal, Aiyush Newcombe, Leslie Slater, Justin Rodriguez, Peter S. Huang, Guowen Fu, Sze Hang Meh, Catherine Wu, Daphne C. Kaul, Rupert Langlois, Marc-André Morawski, Ed Hollander, Andy Eliopoulos, Demetre Aloi, Benjamin Lam, Teresa Abe, Kento T. Rathod, Bhavisha Fazel-Zarandi, Mahya Wang, Jenny Iskilova, Mariam Pasculescu, Adrian Caldwell, Lauren Barrios-Rodiles, Miriam Mohammed-Ali, Zahraa Vas, Nandita Santhanam, Divya Raman Cho, Eo Rin Qu, Kathleen Jha, Shreya Jha, Vedika Suraweera, Wilson Malhotra, Varsha Mastali, Kathy Wen, Richard Sinha, Samir Reid, Angus Gingras, Anne-Claude Chakraborty, Pranesh Slutsky, Arthur S. Jha, Prabhat |
author_sort | Tang, Xuyang |
collection | PubMed |
description | IMPORTANCE: The incidence of infection during SARS-CoV-2 viral waves, the factors associated with infection, and the durability of antibody responses to infection among Canadian adults remain undocumented. OBJECTIVE: To assess the cumulative incidence of SARS-CoV-2 infection during the first 2 viral waves in Canada by measuring seropositivity among adults. DESIGN, SETTING, AND PARTICIPANTS: The Action to Beat Coronavirus study conducted 2 rounds of an online survey about COVID-19 experience and analyzed immunoglobulin G levels based on participant-collected dried blood spots (DBS) to assess the cumulative incidence of SARS-CoV-2 infection during the first and second viral waves in Canada. A sample of 19 994 Canadian adults (aged ≥18 years) was recruited from established members of the Angus Reid Forum, a public polling organization. The study comprised 2 phases (phase 1 from May 1 to September 30, 2020, and phase 2 from December 1, 2020, to March 31, 2021) that generally corresponded to the first (April 1 to July 31, 2020) and second (October 1, 2020, to March 1, 2021) viral waves. MAIN OUTCOMES AND MEASURES: SARS-CoV-2 immunoglobulin G seropositivity (using a chemiluminescence assay) by major geographic and demographic variables and correlation with COVID-19 symptom reporting. RESULTS: Among 19 994 adults who completed the online questionnaire in phase 1, the mean (SD) age was 50.9 (15.4) years, and 10 522 participants (51.9%) were female; 2948 participants (14.5%) had self-identified racial and ethnic minority group status, and 1578 participants (8.2%) were self-identified Indigenous Canadians. Among participants in phase 1, 8967 had DBS testing. In phase 2, 14 621 adults completed online questionnaires, and 7102 of those had DBS testing. Of 19 994 adults who completed the online survey in phase 1, fewer had an educational level of some college or less (4747 individuals [33.1%]) compared with the general population in Canada (45.0%). Survey respondents were otherwise representative of the general population, including in prevalence of known risk factors associated with SARS-CoV-2 infection. The cumulative incidence of SARS-CoV-2 infection among unvaccinated adults increased from 1.9% in phase 1 to 6.5% in phase 2. The seropositivity pattern was demographically and geographically heterogeneous during phase 1 but more homogeneous by phase 2 (with a cumulative incidence ranging from 6.4% to 7.0% in most regions). The exception was the Atlantic region, in which cumulative incidence reached only 3.3% (odds ratio [OR] vs Ontario, 0.46; 95% CI, 0.21-1.02). A total of 47 of 188 adults (25.3%) reporting COVID-19 symptoms during phase 2 were seropositive, and the OR of seropositivity for COVID-19 symptoms was 6.15 (95% CI, 2.02-18.69). In phase 2, 94 of 444 seropositive adults (22.2%) reported having no symptoms. Of 134 seropositive adults in phase 1 who were retested in phase 2, 111 individuals (81.8%) remained seropositive. Participants who had a history of diabetes (OR, 0.58; 95% CI, 0.38-0.90) had lower odds of having detectable antibodies in phase 2. CONCLUSIONS AND RELEVANCE: The Action to Beat Coronavirus study found that the incidence of SARS-CoV-2 infection in Canada was modest until March 2021, and this incidence was lower than the levels of population immunity required to substantially reduce transmission of the virus. Ongoing vaccination efforts remain central to reducing viral transmission and mortality. Assessment of future infection-induced and vaccine-induced immunity is practicable through the use of serial online surveys and participant-collected DBS. |
format | Online Article Text |
id | pubmed-8851304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-88513042022-02-18 Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults Tang, Xuyang Sharma, Abha Pasic, Maria Brown, Patrick Colwill, Karen Gelband, Hellen Birnboim, H. Chaim Nagelkerke, Nico Bogoch, Isaac I. Bansal, Aiyush Newcombe, Leslie Slater, Justin Rodriguez, Peter S. Huang, Guowen Fu, Sze Hang Meh, Catherine Wu, Daphne C. Kaul, Rupert Langlois, Marc-André Morawski, Ed Hollander, Andy Eliopoulos, Demetre Aloi, Benjamin Lam, Teresa Abe, Kento T. Rathod, Bhavisha Fazel-Zarandi, Mahya Wang, Jenny Iskilova, Mariam Pasculescu, Adrian Caldwell, Lauren Barrios-Rodiles, Miriam Mohammed-Ali, Zahraa Vas, Nandita Santhanam, Divya Raman Cho, Eo Rin Qu, Kathleen Jha, Shreya Jha, Vedika Suraweera, Wilson Malhotra, Varsha Mastali, Kathy Wen, Richard Sinha, Samir Reid, Angus Gingras, Anne-Claude Chakraborty, Pranesh Slutsky, Arthur S. Jha, Prabhat JAMA Netw Open Original Investigation IMPORTANCE: The incidence of infection during SARS-CoV-2 viral waves, the factors associated with infection, and the durability of antibody responses to infection among Canadian adults remain undocumented. OBJECTIVE: To assess the cumulative incidence of SARS-CoV-2 infection during the first 2 viral waves in Canada by measuring seropositivity among adults. DESIGN, SETTING, AND PARTICIPANTS: The Action to Beat Coronavirus study conducted 2 rounds of an online survey about COVID-19 experience and analyzed immunoglobulin G levels based on participant-collected dried blood spots (DBS) to assess the cumulative incidence of SARS-CoV-2 infection during the first and second viral waves in Canada. A sample of 19 994 Canadian adults (aged ≥18 years) was recruited from established members of the Angus Reid Forum, a public polling organization. The study comprised 2 phases (phase 1 from May 1 to September 30, 2020, and phase 2 from December 1, 2020, to March 31, 2021) that generally corresponded to the first (April 1 to July 31, 2020) and second (October 1, 2020, to March 1, 2021) viral waves. MAIN OUTCOMES AND MEASURES: SARS-CoV-2 immunoglobulin G seropositivity (using a chemiluminescence assay) by major geographic and demographic variables and correlation with COVID-19 symptom reporting. RESULTS: Among 19 994 adults who completed the online questionnaire in phase 1, the mean (SD) age was 50.9 (15.4) years, and 10 522 participants (51.9%) were female; 2948 participants (14.5%) had self-identified racial and ethnic minority group status, and 1578 participants (8.2%) were self-identified Indigenous Canadians. Among participants in phase 1, 8967 had DBS testing. In phase 2, 14 621 adults completed online questionnaires, and 7102 of those had DBS testing. Of 19 994 adults who completed the online survey in phase 1, fewer had an educational level of some college or less (4747 individuals [33.1%]) compared with the general population in Canada (45.0%). Survey respondents were otherwise representative of the general population, including in prevalence of known risk factors associated with SARS-CoV-2 infection. The cumulative incidence of SARS-CoV-2 infection among unvaccinated adults increased from 1.9% in phase 1 to 6.5% in phase 2. The seropositivity pattern was demographically and geographically heterogeneous during phase 1 but more homogeneous by phase 2 (with a cumulative incidence ranging from 6.4% to 7.0% in most regions). The exception was the Atlantic region, in which cumulative incidence reached only 3.3% (odds ratio [OR] vs Ontario, 0.46; 95% CI, 0.21-1.02). A total of 47 of 188 adults (25.3%) reporting COVID-19 symptoms during phase 2 were seropositive, and the OR of seropositivity for COVID-19 symptoms was 6.15 (95% CI, 2.02-18.69). In phase 2, 94 of 444 seropositive adults (22.2%) reported having no symptoms. Of 134 seropositive adults in phase 1 who were retested in phase 2, 111 individuals (81.8%) remained seropositive. Participants who had a history of diabetes (OR, 0.58; 95% CI, 0.38-0.90) had lower odds of having detectable antibodies in phase 2. CONCLUSIONS AND RELEVANCE: The Action to Beat Coronavirus study found that the incidence of SARS-CoV-2 infection in Canada was modest until March 2021, and this incidence was lower than the levels of population immunity required to substantially reduce transmission of the virus. Ongoing vaccination efforts remain central to reducing viral transmission and mortality. Assessment of future infection-induced and vaccine-induced immunity is practicable through the use of serial online surveys and participant-collected DBS. American Medical Association 2022-02-16 /pmc/articles/PMC8851304/ /pubmed/35171263 http://dx.doi.org/10.1001/jamanetworkopen.2021.46798 Text en Copyright 2022 Tang X et al. JAMA Network Open. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License. |
spellingShingle | Original Investigation Tang, Xuyang Sharma, Abha Pasic, Maria Brown, Patrick Colwill, Karen Gelband, Hellen Birnboim, H. Chaim Nagelkerke, Nico Bogoch, Isaac I. Bansal, Aiyush Newcombe, Leslie Slater, Justin Rodriguez, Peter S. Huang, Guowen Fu, Sze Hang Meh, Catherine Wu, Daphne C. Kaul, Rupert Langlois, Marc-André Morawski, Ed Hollander, Andy Eliopoulos, Demetre Aloi, Benjamin Lam, Teresa Abe, Kento T. Rathod, Bhavisha Fazel-Zarandi, Mahya Wang, Jenny Iskilova, Mariam Pasculescu, Adrian Caldwell, Lauren Barrios-Rodiles, Miriam Mohammed-Ali, Zahraa Vas, Nandita Santhanam, Divya Raman Cho, Eo Rin Qu, Kathleen Jha, Shreya Jha, Vedika Suraweera, Wilson Malhotra, Varsha Mastali, Kathy Wen, Richard Sinha, Samir Reid, Angus Gingras, Anne-Claude Chakraborty, Pranesh Slutsky, Arthur S. Jha, Prabhat Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults |
title | Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults |
title_full | Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults |
title_fullStr | Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults |
title_full_unstemmed | Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults |
title_short | Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults |
title_sort | assessment of sars-cov-2 seropositivity during the first and second viral waves in 2020 and 2021 among canadian adults |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851304/ https://www.ncbi.nlm.nih.gov/pubmed/35171263 http://dx.doi.org/10.1001/jamanetworkopen.2021.46798 |
work_keys_str_mv | AT tangxuyang assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT sharmaabha assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT pasicmaria assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT brownpatrick assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT colwillkaren assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT gelbandhellen assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT birnboimhchaim assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT nagelkerkenico assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT bogochisaaci assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT bansalaiyush assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT newcombeleslie assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT slaterjustin assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT rodriguezpeters assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT huangguowen assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT fuszehang assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT mehcatherine assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT wudaphnec assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT kaulrupert assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT langloismarcandre assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT morawskied assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT hollanderandy assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT eliopoulosdemetre assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT aloibenjamin assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT lamteresa assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT abekentot assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT rathodbhavisha assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT fazelzarandimahya assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT wangjenny assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT iskilovamariam assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT pasculescuadrian assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT caldwelllauren assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT barriosrodilesmiriam assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT mohammedalizahraa assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT vasnandita assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT santhanamdivyaraman assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT choeorin assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT qukathleen assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT jhashreya assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT jhavedika assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT suraweerawilson assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT malhotravarsha assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT mastalikathy assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT wenrichard assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT sinhasamir assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT reidangus assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT gingrasanneclaude assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT chakrabortypranesh assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT slutskyarthurs assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults AT jhaprabhat assessmentofsarscov2seropositivityduringthefirstandsecondviralwavesin2020and2021amongcanadianadults |